nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—ABCG2—Carboplatin—brain cancer	0.0927	0.227	CbGbCtD
Dabrafenib—CYP3A4—Temozolomide—brain cancer	0.0818	0.2	CbGbCtD
Dabrafenib—ABCG2—Etoposide—brain cancer	0.0778	0.191	CbGbCtD
Dabrafenib—CYP3A4—Lomustine—brain cancer	0.0695	0.17	CbGbCtD
Dabrafenib—CYP2C8—Etoposide—brain cancer	0.0414	0.102	CbGbCtD
Dabrafenib—ABCB1—Etoposide—brain cancer	0.0281	0.0687	CbGbCtD
Dabrafenib—SLC22A8—choroid plexus—brain cancer	0.0195	0.155	CbGeAlD
Dabrafenib—CYP3A4—Etoposide—brain cancer	0.0168	0.0412	CbGbCtD
Dabrafenib—NEK11—medulla oblongata—brain cancer	0.00628	0.0501	CbGeAlD
Dabrafenib—LIMK1—telencephalon—brain cancer	0.00572	0.0456	CbGeAlD
Dabrafenib—RAF1—hindbrain—brain cancer	0.00463	0.0369	CbGeAlD
Dabrafenib—NEK11—cerebellum—brain cancer	0.00444	0.0354	CbGeAlD
Dabrafenib—LIMK1—midbrain—brain cancer	0.00411	0.0328	CbGeAlD
Dabrafenib—NEK11—brain—brain cancer	0.00361	0.0288	CbGeAlD
Dabrafenib—LIMK1—cerebellum—brain cancer	0.00318	0.0253	CbGeAlD
Dabrafenib—SIK1—telencephalon—brain cancer	0.00296	0.0236	CbGeAlD
Dabrafenib—BRAF—pituitary gland—brain cancer	0.00288	0.0229	CbGeAlD
Dabrafenib—RAF1—brainstem—brain cancer	0.00265	0.0212	CbGeAlD
Dabrafenib—LIMK1—brain—brain cancer	0.00258	0.0206	CbGeAlD
Dabrafenib—BRAF—midbrain—brain cancer	0.00254	0.0202	CbGeAlD
Dabrafenib—SLCO1B3—pituitary gland—brain cancer	0.00248	0.0198	CbGeAlD
Dabrafenib—SIK1—gonad—brain cancer	0.00247	0.0197	CbGeAlD
Dabrafenib—SIK1—pituitary gland—brain cancer	0.00241	0.0192	CbGeAlD
Dabrafenib—RAF1—telencephalon—brain cancer	0.00235	0.0188	CbGeAlD
Dabrafenib—SIK1—medulla oblongata—brain cancer	0.00232	0.0185	CbGeAlD
Dabrafenib—SIK1—spinal cord—brain cancer	0.00207	0.0165	CbGeAlD
Dabrafenib—RAF1—gonad—brain cancer	0.00196	0.0157	CbGeAlD
Dabrafenib—BRAF—cerebellum—brain cancer	0.00196	0.0157	CbGeAlD
Dabrafenib—SLCO1B3—endocrine gland—brain cancer	0.00192	0.0153	CbGeAlD
Dabrafenib—RAF1—pituitary gland—brain cancer	0.00192	0.0153	CbGeAlD
Dabrafenib—Haemorrhage—Lomustine—brain cancer	0.00191	0.00756	CcSEcCtD
Dabrafenib—SIK1—endocrine gland—brain cancer	0.00187	0.0149	CbGeAlD
Dabrafenib—RAF1—medulla oblongata—brain cancer	0.00185	0.0148	CbGeAlD
Dabrafenib—SIK1—head—brain cancer	0.00184	0.0147	CbGeAlD
Dabrafenib—Rigors—Temozolomide—brain cancer	0.00179	0.00707	CcSEcCtD
Dabrafenib—Gamma-glutamyltransferase increased—Temozolomide—brain cancer	0.00178	0.00702	CcSEcCtD
Dabrafenib—Rash maculo-papular—Hydroxyurea—brain cancer	0.0017	0.00672	CcSEcCtD
Dabrafenib—Neoplasm—Hydroxyurea—brain cancer	0.00169	0.00668	CcSEcCtD
Dabrafenib—RAF1—midbrain—brain cancer	0.00169	0.0135	CbGeAlD
Dabrafenib—Alopecia—Lomustine—brain cancer	0.00169	0.00668	CcSEcCtD
Dabrafenib—SIK1—central nervous system—brain cancer	0.00168	0.0134	CbGeAlD
Dabrafenib—RAF1—spinal cord—brain cancer	0.00165	0.0132	CbGeAlD
Dabrafenib—SIK1—cerebellum—brain cancer	0.00164	0.0131	CbGeAlD
Dabrafenib—Hyperbilirubinaemia—Temozolomide—brain cancer	0.00161	0.00635	CcSEcCtD
Dabrafenib—BRAF—brain—brain cancer	0.00159	0.0127	CbGeAlD
Dabrafenib—Infection—Carboplatin—brain cancer	0.00154	0.0061	CcSEcCtD
Dabrafenib—Leukopenia—Lomustine—brain cancer	0.00149	0.00589	CcSEcCtD
Dabrafenib—Pancreatitis—Procarbazine—brain cancer	0.00149	0.00588	CcSEcCtD
Dabrafenib—RAF1—endocrine gland—brain cancer	0.00149	0.0118	CbGeAlD
Dabrafenib—Renal failure acute—Hydroxyurea—brain cancer	0.00147	0.00581	CcSEcCtD
Dabrafenib—RAF1—head—brain cancer	0.00147	0.0117	CbGeAlD
Dabrafenib—Phosphatase alkaline increased—Temozolomide—brain cancer	0.00146	0.00578	CcSEcCtD
Dabrafenib—Rigors—Etoposide—brain cancer	0.00143	0.00566	CcSEcCtD
Dabrafenib—Dermatitis bullous—Hydroxyurea—brain cancer	0.00142	0.00562	CcSEcCtD
Dabrafenib—Influenza like illness—Temozolomide—brain cancer	0.00142	0.00561	CcSEcCtD
Dabrafenib—Neoplasm—Carmustine—brain cancer	0.00137	0.0054	CcSEcCtD
Dabrafenib—Infection—Lomustine—brain cancer	0.00135	0.00533	CcSEcCtD
Dabrafenib—RAF1—central nervous system—brain cancer	0.00134	0.0107	CbGeAlD
Dabrafenib—SIK1—brain—brain cancer	0.00133	0.0106	CbGeAlD
Dabrafenib—Thrombocytopenia—Lomustine—brain cancer	0.00133	0.00526	CcSEcCtD
Dabrafenib—Neoplasm—Temozolomide—brain cancer	0.00132	0.00522	CcSEcCtD
Dabrafenib—Stomatitis—Procarbazine—brain cancer	0.00132	0.00521	CcSEcCtD
Dabrafenib—RAF1—cerebellum—brain cancer	0.00131	0.0104	CbGeAlD
Dabrafenib—Haematuria—Procarbazine—brain cancer	0.00129	0.0051	CcSEcCtD
Dabrafenib—Cellulitis—Etoposide—brain cancer	0.00129	0.00508	CcSEcCtD
Dabrafenib—Epistaxis—Procarbazine—brain cancer	0.00128	0.00504	CcSEcCtD
Dabrafenib—Blood creatinine increased—Hydroxyurea—brain cancer	0.00127	0.00503	CcSEcCtD
Dabrafenib—Body temperature increased—Carboplatin—brain cancer	0.00123	0.00485	CcSEcCtD
Dabrafenib—Haemoglobin—Procarbazine—brain cancer	0.00122	0.00482	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Temozolomide—brain cancer	0.00122	0.00482	CcSEcCtD
Dabrafenib—Haemorrhage—Procarbazine—brain cancer	0.00121	0.0048	CcSEcCtD
Dabrafenib—Decreased appetite—Lomustine—brain cancer	0.00118	0.00467	CcSEcCtD
Dabrafenib—Phosphatase alkaline increased—Etoposide—brain cancer	0.00117	0.00462	CcSEcCtD
Dabrafenib—Pancreatitis—Hydroxyurea—brain cancer	0.00115	0.00455	CcSEcCtD
Dabrafenib—SLCO1B1—endocrine gland—brain cancer	0.00111	0.00886	CbGeAlD
Dabrafenib—Hyponatraemia—Carmustine—brain cancer	0.0011	0.00436	CcSEcCtD
Dabrafenib—Neutropenia—Hydroxyurea—brain cancer	0.0011	0.00434	CcSEcCtD
Dabrafenib—Chills—Procarbazine—brain cancer	0.00109	0.0043	CcSEcCtD
Dabrafenib—Arrhythmia—Procarbazine—brain cancer	0.00108	0.00429	CcSEcCtD
Dabrafenib—Body temperature increased—Lomustine—brain cancer	0.00107	0.00424	CcSEcCtD
Dabrafenib—Alopecia—Procarbazine—brain cancer	0.00107	0.00424	CcSEcCtD
Dabrafenib—Rash maculo-papular—Etoposide—brain cancer	0.00106	0.0042	CcSEcCtD
Dabrafenib—RAF1—brain—brain cancer	0.00106	0.00847	CbGeAlD
Dabrafenib—Infestation—Hydroxyurea—brain cancer	0.00105	0.00414	CcSEcCtD
Dabrafenib—Infestation NOS—Hydroxyurea—brain cancer	0.00105	0.00414	CcSEcCtD
Dabrafenib—SLC22A6—brain—brain cancer	0.00103	0.00823	CbGeAlD
Dabrafenib—Stomatitis—Hydroxyurea—brain cancer	0.00102	0.00403	CcSEcCtD
Dabrafenib—Hypokalaemia—Carmustine—brain cancer	0.001	0.00395	CcSEcCtD
Dabrafenib—ABCB1—blood vessel—brain cancer	0.00099	0.0079	CbGeAlD
Dabrafenib—Dehydration—Temozolomide—brain cancer	0.000987	0.0039	CcSEcCtD
Dabrafenib—Anaemia—Procarbazine—brain cancer	0.000977	0.00386	CcSEcCtD
Dabrafenib—Blood alkaline phosphatase increased—Etoposide—brain cancer	0.000976	0.00386	CcSEcCtD
Dabrafenib—ABCG2—telencephalon—brain cancer	0.000974	0.00777	CbGeAlD
Dabrafenib—Dry skin—Temozolomide—brain cancer	0.000973	0.00384	CcSEcCtD
Dabrafenib—Hypokalaemia—Temozolomide—brain cancer	0.000966	0.00382	CcSEcCtD
Dabrafenib—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.000956	0.00378	CcSEcCtD
Dabrafenib—Leukopenia—Procarbazine—brain cancer	0.000946	0.00374	CcSEcCtD
Dabrafenib—Haemoglobin—Hydroxyurea—brain cancer	0.000945	0.00373	CcSEcCtD
Dabrafenib—Haemorrhage—Hydroxyurea—brain cancer	0.00094	0.00371	CcSEcCtD
Dabrafenib—Cardiac failure congestive—Etoposide—brain cancer	0.000936	0.0037	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Temozolomide—brain cancer	0.000936	0.0037	CcSEcCtD
Dabrafenib—Cough—Procarbazine—brain cancer	0.000923	0.00364	CcSEcCtD
Dabrafenib—Hypertension—Procarbazine—brain cancer	0.000913	0.00361	CcSEcCtD
Dabrafenib—Myalgia—Procarbazine—brain cancer	0.0009	0.00356	CcSEcCtD
Dabrafenib—Arthralgia—Procarbazine—brain cancer	0.0009	0.00356	CcSEcCtD
Dabrafenib—Neutropenia—Carmustine—brain cancer	0.000888	0.00351	CcSEcCtD
Dabrafenib—Dry mouth—Procarbazine—brain cancer	0.00088	0.00348	CcSEcCtD
Dabrafenib—Vomiting—Lomustine—brain cancer	0.000864	0.00341	CcSEcCtD
Dabrafenib—Oedema—Procarbazine—brain cancer	0.000863	0.00341	CcSEcCtD
Dabrafenib—Neutropenia—Temozolomide—brain cancer	0.000858	0.00339	CcSEcCtD
Dabrafenib—Infection—Procarbazine—brain cancer	0.000857	0.00339	CcSEcCtD
Dabrafenib—Hyperglycaemia—Carmustine—brain cancer	0.000856	0.00338	CcSEcCtD
Dabrafenib—Angiopathy—Hydroxyurea—brain cancer	0.000853	0.00337	CcSEcCtD
Dabrafenib—SLC22A8—head—brain cancer	0.000852	0.0068	CbGeAlD
Dabrafenib—Thrombocytopenia—Procarbazine—brain cancer	0.000845	0.00334	CcSEcCtD
Dabrafenib—Chills—Hydroxyurea—brain cancer	0.000843	0.00333	CcSEcCtD
Dabrafenib—Hyperhidrosis—Procarbazine—brain cancer	0.000834	0.00329	CcSEcCtD
Dabrafenib—Renal failure—Carmustine—brain cancer	0.000832	0.00329	CcSEcCtD
Dabrafenib—Alopecia—Hydroxyurea—brain cancer	0.000831	0.00328	CcSEcCtD
Dabrafenib—Hyperglycaemia—Temozolomide—brain cancer	0.000827	0.00327	CcSEcCtD
Dabrafenib—Stomatitis—Carmustine—brain cancer	0.000825	0.00326	CcSEcCtD
Dabrafenib—Urinary tract infection—Carmustine—brain cancer	0.000823	0.00325	CcSEcCtD
Dabrafenib—Erythema—Hydroxyurea—brain cancer	0.000818	0.00323	CcSEcCtD
Dabrafenib—Infestation NOS—Temozolomide—brain cancer	0.000818	0.00323	CcSEcCtD
Dabrafenib—Infestation—Temozolomide—brain cancer	0.000818	0.00323	CcSEcCtD
Dabrafenib—CYP2C8—pituitary gland—brain cancer	0.000816	0.0065	CbGeAlD
Dabrafenib—Nausea—Lomustine—brain cancer	0.000807	0.00319	CcSEcCtD
Dabrafenib—Hypotension—Procarbazine—brain cancer	0.000806	0.00318	CcSEcCtD
Dabrafenib—Stomatitis—Temozolomide—brain cancer	0.000797	0.00315	CcSEcCtD
Dabrafenib—Urinary tract infection—Temozolomide—brain cancer	0.000795	0.00314	CcSEcCtD
Dabrafenib—ABCG2—pituitary gland—brain cancer	0.000793	0.00632	CbGeAlD
Dabrafenib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000786	0.00311	CcSEcCtD
Dabrafenib—Insomnia—Procarbazine—brain cancer	0.00078	0.00308	CcSEcCtD
Dabrafenib—SLC22A8—central nervous system—brain cancer	0.000778	0.00621	CbGeAlD
Dabrafenib—ABCG2—medulla oblongata—brain cancer	0.000765	0.0061	CbGeAlD
Dabrafenib—Haemoglobin—Carmustine—brain cancer	0.000764	0.00302	CcSEcCtD
Dabrafenib—Haemorrhage—Carmustine—brain cancer	0.00076	0.003	CcSEcCtD
Dabrafenib—Anaemia—Hydroxyurea—brain cancer	0.000756	0.00299	CcSEcCtD
Dabrafenib—Decreased appetite—Procarbazine—brain cancer	0.00075	0.00296	CcSEcCtD
Dabrafenib—Alanine aminotransferase increased—Etoposide—brain cancer	0.000749	0.00296	CcSEcCtD
Dabrafenib—Oedema peripheral—Carmustine—brain cancer	0.000748	0.00296	CcSEcCtD
Dabrafenib—Connective tissue disorder—Carmustine—brain cancer	0.000747	0.00295	CcSEcCtD
Dabrafenib—Fatigue—Procarbazine—brain cancer	0.000744	0.00294	CcSEcCtD
Dabrafenib—Haemoglobin—Temozolomide—brain cancer	0.000738	0.00292	CcSEcCtD
Dabrafenib—Constipation—Procarbazine—brain cancer	0.000738	0.00291	CcSEcCtD
Dabrafenib—Haemorrhage—Temozolomide—brain cancer	0.000734	0.0029	CcSEcCtD
Dabrafenib—Leukopenia—Hydroxyurea—brain cancer	0.000732	0.00289	CcSEcCtD
Dabrafenib—Urinary tract disorder—Temozolomide—brain cancer	0.000725	0.00286	CcSEcCtD
Dabrafenib—Oedema peripheral—Temozolomide—brain cancer	0.000723	0.00286	CcSEcCtD
Dabrafenib—Connective tissue disorder—Temozolomide—brain cancer	0.000722	0.00285	CcSEcCtD
Dabrafenib—Urethral disorder—Temozolomide—brain cancer	0.00072	0.00284	CcSEcCtD
Dabrafenib—Eye disorder—Carmustine—brain cancer	0.00071	0.0028	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Procarbazine—brain cancer	0.000706	0.00279	CcSEcCtD
Dabrafenib—ABCG2—midbrain—brain cancer	0.000699	0.00558	CbGeAlD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—brain cancer	0.000692	0.00273	CcSEcCtD
Dabrafenib—Neutropenia—Etoposide—brain cancer	0.000686	0.00271	CcSEcCtD
Dabrafenib—Eye disorder—Temozolomide—brain cancer	0.000686	0.00271	CcSEcCtD
Dabrafenib—ABCG2—spinal cord—brain cancer	0.000682	0.00544	CbGeAlD
Dabrafenib—Abdominal pain—Procarbazine—brain cancer	0.000682	0.00269	CcSEcCtD
Dabrafenib—Body temperature increased—Procarbazine—brain cancer	0.000682	0.00269	CcSEcCtD
Dabrafenib—Arrhythmia—Carmustine—brain cancer	0.000679	0.00268	CcSEcCtD
Dabrafenib—Alopecia—Carmustine—brain cancer	0.000671	0.00265	CcSEcCtD
Dabrafenib—Oedema—Hydroxyurea—brain cancer	0.000668	0.00264	CcSEcCtD
Dabrafenib—Angiopathy—Temozolomide—brain cancer	0.000666	0.00263	CcSEcCtD
Dabrafenib—Mental disorder—Carmustine—brain cancer	0.000666	0.00263	CcSEcCtD
Dabrafenib—Infection—Hydroxyurea—brain cancer	0.000663	0.00262	CcSEcCtD
Dabrafenib—Immune system disorder—Temozolomide—brain cancer	0.000663	0.00262	CcSEcCtD
Dabrafenib—Mediastinal disorder—Temozolomide—brain cancer	0.000662	0.00261	CcSEcCtD
Dabrafenib—Malnutrition—Carmustine—brain cancer	0.000661	0.00261	CcSEcCtD
Dabrafenib—Erythema—Carmustine—brain cancer	0.000661	0.00261	CcSEcCtD
Dabrafenib—Chills—Temozolomide—brain cancer	0.000659	0.0026	CcSEcCtD
Dabrafenib—Nervous system disorder—Hydroxyurea—brain cancer	0.000655	0.00259	CcSEcCtD
Dabrafenib—Infestation—Etoposide—brain cancer	0.000654	0.00259	CcSEcCtD
Dabrafenib—Infestation NOS—Etoposide—brain cancer	0.000654	0.00259	CcSEcCtD
Dabrafenib—Thrombocytopenia—Hydroxyurea—brain cancer	0.000654	0.00258	CcSEcCtD
Dabrafenib—Alopecia—Temozolomide—brain cancer	0.000649	0.00256	CcSEcCtD
Dabrafenib—Skin disorder—Hydroxyurea—brain cancer	0.000649	0.00256	CcSEcCtD
Dabrafenib—Renal failure—Etoposide—brain cancer	0.000643	0.00254	CcSEcCtD
Dabrafenib—Mental disorder—Temozolomide—brain cancer	0.000643	0.00254	CcSEcCtD
Dabrafenib—Back pain—Carmustine—brain cancer	0.00064	0.00253	CcSEcCtD
Dabrafenib—Erythema—Temozolomide—brain cancer	0.000639	0.00252	CcSEcCtD
Dabrafenib—Malnutrition—Temozolomide—brain cancer	0.000639	0.00252	CcSEcCtD
Dabrafenib—Stomatitis—Etoposide—brain cancer	0.000638	0.00252	CcSEcCtD
Dabrafenib—Hypersensitivity—Procarbazine—brain cancer	0.000636	0.00251	CcSEcCtD
Dabrafenib—CYP2C8—endocrine gland—brain cancer	0.000632	0.00504	CbGeAlD
Dabrafenib—Vision blurred—Carmustine—brain cancer	0.000623	0.00246	CcSEcCtD
Dabrafenib—Asthenia—Procarbazine—brain cancer	0.000619	0.00245	CcSEcCtD
Dabrafenib—Back pain—Temozolomide—brain cancer	0.000618	0.00244	CcSEcCtD
Dabrafenib—SLC22A8—brain—brain cancer	0.000618	0.00493	CbGeAlD
Dabrafenib—Anaemia—Carmustine—brain cancer	0.000611	0.00241	CcSEcCtD
Dabrafenib—Pruritus—Procarbazine—brain cancer	0.00061	0.00241	CcSEcCtD
Dabrafenib—Vision blurred—Temozolomide—brain cancer	0.000602	0.00238	CcSEcCtD
Dabrafenib—Leukopenia—Carmustine—brain cancer	0.000592	0.00234	CcSEcCtD
Dabrafenib—Anaemia—Temozolomide—brain cancer	0.000591	0.00233	CcSEcCtD
Dabrafenib—Diarrhoea—Procarbazine—brain cancer	0.00059	0.00233	CcSEcCtD
Dabrafenib—Decreased appetite—Hydroxyurea—brain cancer	0.00058	0.00229	CcSEcCtD
Dabrafenib—Urinary tract disorder—Etoposide—brain cancer	0.00058	0.00229	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000576	0.00228	CcSEcCtD
Dabrafenib—Urethral disorder—Etoposide—brain cancer	0.000576	0.00228	CcSEcCtD
Dabrafenib—Fatigue—Hydroxyurea—brain cancer	0.000576	0.00227	CcSEcCtD
Dabrafenib—Leukopenia—Temozolomide—brain cancer	0.000572	0.00226	CcSEcCtD
Dabrafenib—Hypertension—Carmustine—brain cancer	0.000571	0.00226	CcSEcCtD
Dabrafenib—Constipation—Hydroxyurea—brain cancer	0.000571	0.00226	CcSEcCtD
Dabrafenib—Dizziness—Procarbazine—brain cancer	0.000571	0.00225	CcSEcCtD
Dabrafenib—Myalgia—Carmustine—brain cancer	0.000563	0.00222	CcSEcCtD
Dabrafenib—Cough—Temozolomide—brain cancer	0.000558	0.0022	CcSEcCtD
Dabrafenib—Hypertension—Temozolomide—brain cancer	0.000552	0.00218	CcSEcCtD
Dabrafenib—Eye disorder—Etoposide—brain cancer	0.000549	0.00217	CcSEcCtD
Dabrafenib—Vomiting—Procarbazine—brain cancer	0.000549	0.00217	CcSEcCtD
Dabrafenib—Myalgia—Temozolomide—brain cancer	0.000544	0.00215	CcSEcCtD
Dabrafenib—Arthralgia—Temozolomide—brain cancer	0.000544	0.00215	CcSEcCtD
Dabrafenib—Rash—Procarbazine—brain cancer	0.000544	0.00215	CcSEcCtD
Dabrafenib—Dermatitis—Procarbazine—brain cancer	0.000544	0.00215	CcSEcCtD
Dabrafenib—ABCG2—cerebellum—brain cancer	0.000541	0.00432	CbGeAlD
Dabrafenib—Headache—Procarbazine—brain cancer	0.000541	0.00214	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—brain cancer	0.00054	0.00213	CcSEcCtD
Dabrafenib—Oedema—Carmustine—brain cancer	0.00054	0.00213	CcSEcCtD
Dabrafenib—Infection—Carmustine—brain cancer	0.000536	0.00212	CcSEcCtD
Dabrafenib—Angiopathy—Etoposide—brain cancer	0.000533	0.00211	CcSEcCtD
Dabrafenib—Dry mouth—Temozolomide—brain cancer	0.000532	0.0021	CcSEcCtD
Dabrafenib—Immune system disorder—Etoposide—brain cancer	0.000531	0.0021	CcSEcCtD
Dabrafenib—Mediastinal disorder—Etoposide—brain cancer	0.00053	0.00209	CcSEcCtD
Dabrafenib—Thrombocytopenia—Carmustine—brain cancer	0.000529	0.00209	CcSEcCtD
Dabrafenib—Body temperature increased—Hydroxyurea—brain cancer	0.000528	0.00209	CcSEcCtD
Dabrafenib—Chills—Etoposide—brain cancer	0.000527	0.00208	CcSEcCtD
Dabrafenib—Oedema—Temozolomide—brain cancer	0.000522	0.00206	CcSEcCtD
Dabrafenib—Alopecia—Etoposide—brain cancer	0.000519	0.00205	CcSEcCtD
Dabrafenib—Infection—Temozolomide—brain cancer	0.000518	0.00205	CcSEcCtD
Dabrafenib—Nausea—Procarbazine—brain cancer	0.000512	0.00202	CcSEcCtD
Dabrafenib—Nervous system disorder—Temozolomide—brain cancer	0.000512	0.00202	CcSEcCtD
Dabrafenib—Thrombocytopenia—Temozolomide—brain cancer	0.000511	0.00202	CcSEcCtD
Dabrafenib—Skin disorder—Temozolomide—brain cancer	0.000507	0.002	CcSEcCtD
Dabrafenib—Hypotension—Carmustine—brain cancer	0.000504	0.00199	CcSEcCtD
Dabrafenib—Hyperhidrosis—Temozolomide—brain cancer	0.000504	0.00199	CcSEcCtD
Dabrafenib—Back pain—Etoposide—brain cancer	0.000495	0.00195	CcSEcCtD
Dabrafenib—Hypersensitivity—Hydroxyurea—brain cancer	0.000492	0.00194	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000492	0.00194	CcSEcCtD
Dabrafenib—Muscle spasms—Etoposide—brain cancer	0.000492	0.00194	CcSEcCtD
Dabrafenib—Insomnia—Carmustine—brain cancer	0.000488	0.00193	CcSEcCtD
Dabrafenib—ABCB1—telencephalon—brain cancer	0.00048	0.00383	CbGeAlD
Dabrafenib—Asthenia—Hydroxyurea—brain cancer	0.000479	0.00189	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000475	0.00188	CcSEcCtD
Dabrafenib—Anaemia—Etoposide—brain cancer	0.000473	0.00187	CcSEcCtD
Dabrafenib—Insomnia—Temozolomide—brain cancer	0.000472	0.00186	CcSEcCtD
Dabrafenib—Decreased appetite—Carmustine—brain cancer	0.000469	0.00185	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Carmustine—brain cancer	0.000466	0.00184	CcSEcCtD
Dabrafenib—Constipation—Carmustine—brain cancer	0.000462	0.00182	CcSEcCtD
Dabrafenib—Leukopenia—Etoposide—brain cancer	0.000458	0.00181	CcSEcCtD
Dabrafenib—Diarrhoea—Hydroxyurea—brain cancer	0.000457	0.0018	CcSEcCtD
Dabrafenib—Decreased appetite—Temozolomide—brain cancer	0.000453	0.00179	CcSEcCtD
Dabrafenib—CYP2C8—brain—brain cancer	0.000452	0.00361	CbGeAlD
Dabrafenib—Gastrointestinal disorder—Temozolomide—brain cancer	0.00045	0.00178	CcSEcCtD
Dabrafenib—Fatigue—Temozolomide—brain cancer	0.00045	0.00178	CcSEcCtD
Dabrafenib—Cough—Etoposide—brain cancer	0.000446	0.00176	CcSEcCtD
Dabrafenib—Constipation—Temozolomide—brain cancer	0.000446	0.00176	CcSEcCtD
Dabrafenib—Hypertension—Etoposide—brain cancer	0.000442	0.00174	CcSEcCtD
Dabrafenib—Dizziness—Hydroxyurea—brain cancer	0.000442	0.00174	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Carmustine—brain cancer	0.000441	0.00174	CcSEcCtD
Dabrafenib—ABCG2—brain—brain cancer	0.000439	0.00351	CbGeAlD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—brain cancer	0.000432	0.00171	CcSEcCtD
Dabrafenib—CYP3A4—endocrine gland—brain cancer	0.000428	0.00341	CbGeAlD
Dabrafenib—Abdominal pain—Carmustine—brain cancer	0.000427	0.00169	CcSEcCtD
Dabrafenib—Body temperature increased—Carmustine—brain cancer	0.000427	0.00169	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Temozolomide—brain cancer	0.000427	0.00169	CcSEcCtD
Dabrafenib—Vomiting—Hydroxyurea—brain cancer	0.000425	0.00168	CcSEcCtD
Dabrafenib—Rash—Hydroxyurea—brain cancer	0.000421	0.00166	CcSEcCtD
Dabrafenib—Dermatitis—Hydroxyurea—brain cancer	0.000421	0.00166	CcSEcCtD
Dabrafenib—Headache—Hydroxyurea—brain cancer	0.000418	0.00165	CcSEcCtD
Dabrafenib—Infection—Etoposide—brain cancer	0.000415	0.00164	CcSEcCtD
Dabrafenib—Abdominal pain—Temozolomide—brain cancer	0.000412	0.00163	CcSEcCtD
Dabrafenib—Body temperature increased—Temozolomide—brain cancer	0.000412	0.00163	CcSEcCtD
Dabrafenib—Thrombocytopenia—Etoposide—brain cancer	0.000409	0.00161	CcSEcCtD
Dabrafenib—Skin disorder—Etoposide—brain cancer	0.000405	0.0016	CcSEcCtD
Dabrafenib—Hyperhidrosis—Etoposide—brain cancer	0.000404	0.00159	CcSEcCtD
Dabrafenib—ABCB1—gonad—brain cancer	0.000401	0.0032	CbGeAlD
Dabrafenib—Hypersensitivity—Carmustine—brain cancer	0.000398	0.00157	CcSEcCtD
Dabrafenib—Nausea—Hydroxyurea—brain cancer	0.000397	0.00157	CcSEcCtD
Dabrafenib—ABCB1—pituitary gland—brain cancer	0.000391	0.00312	CbGeAlD
Dabrafenib—Hypotension—Etoposide—brain cancer	0.00039	0.00154	CcSEcCtD
Dabrafenib—Asthenia—Carmustine—brain cancer	0.000387	0.00153	CcSEcCtD
Dabrafenib—CYP3A4—central nervous system—brain cancer	0.000386	0.00308	CbGeAlD
Dabrafenib—Hypersensitivity—Temozolomide—brain cancer	0.000384	0.00152	CcSEcCtD
Dabrafenib—ABCB1—medulla oblongata—brain cancer	0.000377	0.00301	CbGeAlD
Dabrafenib—Asthenia—Temozolomide—brain cancer	0.000374	0.00148	CcSEcCtD
Dabrafenib—Diarrhoea—Carmustine—brain cancer	0.000369	0.00146	CcSEcCtD
Dabrafenib—Pruritus—Temozolomide—brain cancer	0.000369	0.00146	CcSEcCtD
Dabrafenib—Decreased appetite—Etoposide—brain cancer	0.000363	0.00143	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Etoposide—brain cancer	0.00036	0.00142	CcSEcCtD
Dabrafenib—Fatigue—Etoposide—brain cancer	0.00036	0.00142	CcSEcCtD
Dabrafenib—Dizziness—Carmustine—brain cancer	0.000357	0.00141	CcSEcCtD
Dabrafenib—Constipation—Etoposide—brain cancer	0.000357	0.00141	CcSEcCtD
Dabrafenib—Diarrhoea—Temozolomide—brain cancer	0.000357	0.00141	CcSEcCtD
Dabrafenib—Dizziness—Temozolomide—brain cancer	0.000345	0.00136	CcSEcCtD
Dabrafenib—ABCB1—midbrain—brain cancer	0.000345	0.00275	CbGeAlD
Dabrafenib—Vomiting—Carmustine—brain cancer	0.000343	0.00136	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Etoposide—brain cancer	0.000341	0.00135	CcSEcCtD
Dabrafenib—Rash—Carmustine—brain cancer	0.00034	0.00134	CcSEcCtD
Dabrafenib—Dermatitis—Carmustine—brain cancer	0.00034	0.00134	CcSEcCtD
Dabrafenib—Headache—Carmustine—brain cancer	0.000338	0.00134	CcSEcCtD
Dabrafenib—ABCB1—spinal cord—brain cancer	0.000336	0.00268	CbGeAlD
Dabrafenib—Vomiting—Temozolomide—brain cancer	0.000332	0.00131	CcSEcCtD
Dabrafenib—Abdominal pain—Etoposide—brain cancer	0.00033	0.0013	CcSEcCtD
Dabrafenib—Body temperature increased—Etoposide—brain cancer	0.00033	0.0013	CcSEcCtD
Dabrafenib—Rash—Temozolomide—brain cancer	0.000329	0.0013	CcSEcCtD
Dabrafenib—Dermatitis—Temozolomide—brain cancer	0.000329	0.0013	CcSEcCtD
Dabrafenib—Headache—Temozolomide—brain cancer	0.000327	0.00129	CcSEcCtD
Dabrafenib—Nausea—Carmustine—brain cancer	0.000321	0.00127	CcSEcCtD
Dabrafenib—Nausea—Temozolomide—brain cancer	0.00031	0.00122	CcSEcCtD
Dabrafenib—Hypersensitivity—Etoposide—brain cancer	0.000308	0.00121	CcSEcCtD
Dabrafenib—ABCB1—endocrine gland—brain cancer	0.000303	0.00242	CbGeAlD
Dabrafenib—Asthenia—Etoposide—brain cancer	0.000299	0.00118	CcSEcCtD
Dabrafenib—ABCB1—head—brain cancer	0.000299	0.00239	CbGeAlD
Dabrafenib—Pruritus—Etoposide—brain cancer	0.000295	0.00117	CcSEcCtD
Dabrafenib—Diarrhoea—Etoposide—brain cancer	0.000286	0.00113	CcSEcCtD
Dabrafenib—Dizziness—Etoposide—brain cancer	0.000276	0.00109	CcSEcCtD
Dabrafenib—ABCB1—central nervous system—brain cancer	0.000273	0.00218	CbGeAlD
Dabrafenib—ABCB1—cerebellum—brain cancer	0.000267	0.00213	CbGeAlD
Dabrafenib—Vomiting—Etoposide—brain cancer	0.000265	0.00105	CcSEcCtD
Dabrafenib—Rash—Etoposide—brain cancer	0.000263	0.00104	CcSEcCtD
Dabrafenib—Dermatitis—Etoposide—brain cancer	0.000263	0.00104	CcSEcCtD
Dabrafenib—Headache—Etoposide—brain cancer	0.000261	0.00103	CcSEcCtD
Dabrafenib—Nausea—Etoposide—brain cancer	0.000248	0.000979	CcSEcCtD
Dabrafenib—ABCB1—brain—brain cancer	0.000217	0.00173	CbGeAlD
Dabrafenib—RAF1—PDGFR-beta signaling pathway—MYC—brain cancer	0.000101	0.000471	CbGpPWpGaD
Dabrafenib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	0.0001	0.00047	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—STAT3—brain cancer	9.83e-05	0.000461	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ABR—brain cancer	9.72e-05	0.000455	CbGpPWpGaD
Dabrafenib—RAF1—BDNF signaling pathway—STAT3—brain cancer	9.66e-05	0.000453	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—MYC—brain cancer	9.63e-05	0.000451	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—EGFR—brain cancer	9.53e-05	0.000447	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—ERBB2—brain cancer	9.51e-05	0.000446	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—TP53—brain cancer	9.49e-05	0.000445	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—TRPC6—brain cancer	9.48e-05	0.000444	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—EGFR—brain cancer	9.47e-05	0.000444	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TP53—brain cancer	9.42e-05	0.000442	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VAV1—brain cancer	9.4e-05	0.000441	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GLI2—brain cancer	9.38e-05	0.00044	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—IDH1—brain cancer	9.36e-05	0.000439	CbGpPWpGaD
Dabrafenib—BRAF—Disease—SHH—brain cancer	9.11e-05	0.000427	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ENO2—brain cancer	9.11e-05	0.000427	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—CCND1—brain cancer	8.97e-05	0.00042	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—EGFR—brain cancer	8.93e-05	0.000419	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	8.93e-05	0.000419	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—CTNNB1—brain cancer	8.88e-05	0.000416	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	8.84e-05	0.000415	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—STAT3—brain cancer	8.84e-05	0.000414	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GLI1—brain cancer	8.82e-05	0.000414	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—STAT3—brain cancer	8.79e-05	0.000412	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	8.79e-05	0.000412	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL2—brain cancer	8.75e-05	0.00041	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	8.62e-05	0.000404	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CYP2C9—brain cancer	8.6e-05	0.000403	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	8.59e-05	0.000403	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTCH2—brain cancer	8.57e-05	0.000402	CbGpPWpGaD
Dabrafenib—RAF1—Regulation of Actin Cytoskeleton—EGFR—brain cancer	8.55e-05	0.000401	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—EGFR—brain cancer	8.55e-05	0.000401	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	8.52e-05	0.000399	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—VAV1—brain cancer	8.47e-05	0.000397	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—EGFR—brain cancer	8.41e-05	0.000394	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—EGFR—brain cancer	8.36e-05	0.000392	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SUFU—brain cancer	8.36e-05	0.000392	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HES5—brain cancer	8.3e-05	0.000389	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—HES1—brain cancer	8.24e-05	0.000386	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—STAT3—brain cancer	8.19e-05	0.000384	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—IL2—brain cancer	8.15e-05	0.000382	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—VAV1—brain cancer	8.13e-05	0.000381	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—IDH1—brain cancer	8.11e-05	0.00038	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—GFAP—brain cancer	8.07e-05	0.000378	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—STAT3—brain cancer	8.07e-05	0.000378	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STRADA—brain cancer	8.05e-05	0.000378	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—EGFR—brain cancer	8.03e-05	0.000377	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—STAT3—brain cancer	8.01e-05	0.000376	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—EGFR—brain cancer	7.99e-05	0.000375	CbGpPWpGaD
Dabrafenib—RAF1—EGF/EGFR Signaling Pathway—EGFR—brain cancer	7.99e-05	0.000375	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IDH1—brain cancer	7.97e-05	0.000374	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CYP2C9—brain cancer	7.96e-05	0.000373	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—EGFR—brain cancer	7.95e-05	0.000373	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—MYC—brain cancer	7.94e-05	0.000372	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	7.92e-05	0.000371	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—EGFR—brain cancer	7.91e-05	0.000371	CbGpPWpGaD
Dabrafenib—RAF1—TGF-beta Signaling Pathway—TP53—brain cancer	7.91e-05	0.000371	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—VEGFA—brain cancer	7.82e-05	0.000366	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	7.79e-05	0.000365	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—EGFR—brain cancer	7.76e-05	0.000364	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HEY1—brain cancer	7.65e-05	0.000359	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	7.62e-05	0.000357	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HEY1—brain cancer	7.56e-05	0.000354	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	7.54e-05	0.000354	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—DLL1—brain cancer	7.5e-05	0.000352	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—RELA—brain cancer	7.49e-05	0.000351	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—SHH—brain cancer	7.47e-05	0.00035	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—EGFR—brain cancer	7.45e-05	0.000349	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—EGFR—brain cancer	7.45e-05	0.000349	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—EGFR—brain cancer	7.45e-05	0.000349	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—VEGFA—brain cancer	7.44e-05	0.000349	CbGpPWpGaD
Dabrafenib—RAF1—Disease—DLL1—brain cancer	7.41e-05	0.000347	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ENO2—brain cancer	7.4e-05	0.000347	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—EGFR—brain cancer	7.38e-05	0.000346	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—RELA—brain cancer	7.36e-05	0.000345	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—EGFR—brain cancer	7.33e-05	0.000344	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—ERBB2—brain cancer	7.32e-05	0.000343	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—EGFR—brain cancer	7.31e-05	0.000343	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—BSG—brain cancer	7.31e-05	0.000343	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—EGFR—brain cancer	7.28e-05	0.000341	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—STAT3—brain cancer	7.26e-05	0.00034	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TRPC6—brain cancer	7.2e-05	0.000338	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	7.16e-05	0.000336	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—SMO—brain cancer	7.08e-05	0.000332	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PTCH1—brain cancer	7.08e-05	0.000332	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—RELA—brain cancer	7.07e-05	0.000332	CbGpPWpGaD
Dabrafenib—RAF1—Focal Adhesion—EGFR—brain cancer	7.04e-05	0.00033	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—ERBB2—brain cancer	7.03e-05	0.000329	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	7.01e-05	0.000328	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—PDGFRA—brain cancer	6.93e-05	0.000325	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—brain cancer	6.93e-05	0.000325	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—BSG—brain cancer	6.77e-05	0.000317	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL2—brain cancer	6.75e-05	0.000316	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ABR—brain cancer	6.72e-05	0.000315	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—PDGFRA—brain cancer	6.66e-05	0.000312	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—ERBB2—brain cancer	6.62e-05	0.00031	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—EGFR—brain cancer	6.6e-05	0.000309	CbGpPWpGaD
Dabrafenib—BRAF—Disease—VAV1—brain cancer	6.58e-05	0.000308	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	6.52e-05	0.000306	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TP53—brain cancer	6.52e-05	0.000306	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GLI2—brain cancer	6.49e-05	0.000304	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—SKP2—brain cancer	6.47e-05	0.000303	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CDK4—brain cancer	6.47e-05	0.000303	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SHH—brain cancer	6.38e-05	0.000299	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—brain cancer	6.37e-05	0.000299	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL2—brain cancer	6.37e-05	0.000299	CbGpPWpGaD
Dabrafenib—RAF1—Disease—SHH—brain cancer	6.3e-05	0.000295	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ENO2—brain cancer	6.3e-05	0.000295	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—IDH1—brain cancer	6.29e-05	0.000295	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TRPC6—brain cancer	6.15e-05	0.000288	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CTNNB1—brain cancer	6.15e-05	0.000288	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	6.14e-05	0.000288	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GLI1—brain cancer	6.1e-05	0.000286	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IRS2—brain cancer	6.09e-05	0.000285	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SMO—brain cancer	6.05e-05	0.000283	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTCH1—brain cancer	6.05e-05	0.000283	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—PIK3CG—brain cancer	5.97e-05	0.00028	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	5.88e-05	0.000276	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—IRS2—brain cancer	5.84e-05	0.000274	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—IDH1—brain cancer	5.82e-05	0.000273	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SUFU—brain cancer	5.79e-05	0.000271	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—STAT3—brain cancer	5.68e-05	0.000266	CbGpPWpGaD
Dabrafenib—BRAF—Disease—HES1—brain cancer	5.66e-05	0.000265	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GFAP—brain cancer	5.58e-05	0.000262	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—STAT3—brain cancer	5.58e-05	0.000262	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—VAV1—brain cancer	5.4e-05	0.000253	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PDGFRA—brain cancer	5.39e-05	0.000253	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—STAT3—brain cancer	5.36e-05	0.000251	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HEY1—brain cancer	5.29e-05	0.000248	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—DLL1—brain cancer	5.19e-05	0.000243	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	5.12e-05	0.00024	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	5.12e-05	0.00024	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—VEGFA—brain cancer	5.1e-05	0.000239	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—EGFR—brain cancer	5.07e-05	0.000238	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ENO2—brain cancer	4.97e-05	0.000233	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CYP2C9—brain cancer	4.94e-05	0.000232	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—VAV1—brain cancer	4.93e-05	0.000231	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—EGFR—brain cancer	4.87e-05	0.000228	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOTCH2—brain cancer	4.83e-05	0.000227	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	4.77e-05	0.000223	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—RELA—brain cancer	4.76e-05	0.000223	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IRS2—brain cancer	4.73e-05	0.000222	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—ERBB2—brain cancer	4.73e-05	0.000222	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VAV1—brain cancer	4.61e-05	0.000216	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ENO2—brain cancer	4.6e-05	0.000216	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—EGFR—brain cancer	4.59e-05	0.000215	CbGpPWpGaD
Dabrafenib—RAF1—Disease—VAV1—brain cancer	4.55e-05	0.000213	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SHH—brain cancer	4.41e-05	0.000207	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CYP2C9—brain cancer	4.31e-05	0.000202	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TRPC6—brain cancer	4.26e-05	0.000199	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	4.21e-05	0.000197	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—BSG—brain cancer	4.2e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—brain cancer	4.2e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—RELA—brain cancer	4.2e-05	0.000197	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTCH1—brain cancer	4.18e-05	0.000196	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SMO—brain cancer	4.18e-05	0.000196	CbGpPWpGaD
Dabrafenib—BRAF—Disease—APC—brain cancer	4.18e-05	0.000196	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ERBB2—brain cancer	4.17e-05	0.000196	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	4.17e-05	0.000195	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—CTNNB1—brain cancer	4.14e-05	0.000194	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PDGFRA—brain cancer	4.04e-05	0.000189	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—RELA—brain cancer	4.03e-05	0.000189	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—ERBB2—brain cancer	4.01e-05	0.000188	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—HES1—brain cancer	3.96e-05	0.000186	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HES1—brain cancer	3.92e-05	0.000184	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PDGFRA—brain cancer	3.77e-05	0.000177	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PDGFRA—brain cancer	3.73e-05	0.000175	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	3.67e-05	0.000172	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SPP1—brain cancer	3.66e-05	0.000172	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BSG—brain cancer	3.66e-05	0.000172	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CTNNB1—brain cancer	3.65e-05	0.000171	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—brain cancer	3.64e-05	0.000171	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—IDH1—brain cancer	3.61e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—STAT3—brain cancer	3.6e-05	0.000169	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—brain cancer	3.57e-05	0.000167	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IRS2—brain cancer	3.55e-05	0.000166	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—PIK3CG—brain cancer	3.43e-05	0.000161	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PIK3CG—brain cancer	3.39e-05	0.000159	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	3.38e-05	0.000158	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOTCH2—brain cancer	3.34e-05	0.000157	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IRS2—brain cancer	3.31e-05	0.000155	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	3.3e-05	0.000155	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—EGFR—brain cancer	3.28e-05	0.000154	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IRS2—brain cancer	3.27e-05	0.000153	CbGpPWpGaD
Dabrafenib—BRAF—Disease—ERBB2—brain cancer	3.24e-05	0.000152	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VAV1—brain cancer	3.19e-05	0.000149	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—IDH1—brain cancer	3.15e-05	0.000148	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	2.94e-05	0.000138	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—APC—brain cancer	2.93e-05	0.000137	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PIK3CG—brain cancer	2.93e-05	0.000137	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—EGFR—brain cancer	2.89e-05	0.000136	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APC—brain cancer	2.89e-05	0.000136	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO2—brain cancer	2.86e-05	0.000134	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CTNNB1—brain cancer	2.84e-05	0.000133	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—EGFR—brain cancer	2.78e-05	0.00013	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	2.77e-05	0.00013	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—HES1—brain cancer	2.74e-05	0.000129	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—brain cancer	2.7e-05	0.000126	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CYP2C9—brain cancer	2.65e-05	0.000124	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PDGFRA—brain cancer	2.61e-05	0.000122	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SPP1—brain cancer	2.53e-05	0.000119	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO2—brain cancer	2.49e-05	0.000117	CbGpPWpGaD
Dabrafenib—BRAF—Disease—STAT3—brain cancer	2.47e-05	0.000116	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—RELA—brain cancer	2.45e-05	0.000115	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ERBB2—brain cancer	2.43e-05	0.000114	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—brain cancer	2.41e-05	0.000113	CbGpPWpGaD
Dabrafenib—BRAF—Disease—MYC—brain cancer	2.3e-05	0.000108	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IRS2—brain cancer	2.29e-05	0.000107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—RELA—brain cancer	2.29e-05	0.000107	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PIK3CG—brain cancer	2.28e-05	0.000107	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ERBB2—brain cancer	2.27e-05	0.000106	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BSG—brain cancer	2.26e-05	0.000106	CbGpPWpGaD
Dabrafenib—BRAF—Disease—EGFR—brain cancer	2.25e-05	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Disease—ERBB2—brain cancer	2.24e-05	0.000105	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—brain cancer	2.2e-05	0.000103	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CTNNB1—brain cancer	2.13e-05	9.97e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PIK3CG—brain cancer	2.11e-05	9.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—brain cancer	2.06e-05	9.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PIK3CG—brain cancer	2.02e-05	9.49e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—APC—brain cancer	2.02e-05	9.49e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCND1—brain cancer	2.01e-05	9.41e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CTNNB1—brain cancer	1.99e-05	9.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CTNNB1—brain cancer	1.96e-05	9.21e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—IDH1—brain cancer	1.94e-05	9.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—STAT3—brain cancer	1.85e-05	8.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—EGFR—brain cancer	1.84e-05	8.64e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—brain cancer	1.75e-05	8.2e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT3—brain cancer	1.73e-05	8.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT3—brain cancer	1.71e-05	8.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—EGFR—brain cancer	1.69e-05	7.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MYC—brain cancer	1.61e-05	7.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MYC—brain cancer	1.59e-05	7.46e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RELA—brain cancer	1.58e-05	7.41e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—EGFR—brain cancer	1.57e-05	7.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ERBB2—brain cancer	1.57e-05	7.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—EGFR—brain cancer	1.56e-05	7.29e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO2—brain cancer	1.53e-05	7.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—brain cancer	1.42e-05	6.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCND1—brain cancer	1.39e-05	6.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CTNNB1—brain cancer	1.38e-05	6.45e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—brain cancer	1.32e-05	6.2e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PIK3CG—brain cancer	1.31e-05	6.14e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—brain cancer	1.21e-05	5.67e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT3—brain cancer	1.2e-05	5.62e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PIK3CG—brain cancer	1.14e-05	5.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MYC—brain cancer	1.11e-05	5.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—EGFR—brain cancer	1.09e-05	5.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—brain cancer	9.15e-06	4.29e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PIK3CG—brain cancer	7.03e-06	3.3e-05	CbGpPWpGaD
